Lu, C., Kang, T., Zhang, J., Yang, K., Liu, Y., Song, K., Lin, Q., Dixit, D., Gimple, R. C., Zhang, Q., Shi, Z., Fan, X., Wu, Q., Li, D., Shan, D., Gao, J., Gu, D., You, H., Li, Y., … Wang, X. (2025). Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-58366-5

Haile, H., Upadhyayula, P. S., Karlovich, E., Sisti, M. B., Gill, B. J. A., & Donovan, L. E. (2025). Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report. Acta Neuropathologica Communications, 13(1). https://doi.org/10.1186/s40478-024-01894-w

Diaz, M., & Pan, P. C. (2025). Management of Low-Grade Gliomas. The Cancer Journal, 31(1). https://doi.org/10.1097/ppo.0000000000000760

Gao, J., Gu, D., Yang, K., Zhang, J., Lin, Q., Yuan, W., Zhu, X., Dixit, D., Gimple, R. C., You, H., Zhang, Q., Shi, Z., Fan, X., Wu, Q., Lu, C., Cheng, Z., Li, D., Zhao, L., Xue, B., … Wang, X. (2025). Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding. Cancer Cell, 43(1), 122-143.e8. https://doi.org/10.1016/j.ccell.2024.12.006

Kazemi, F., Ahmed, A. K., Roy, J. M., Kuo, C. C., Jimenez, A. E., Rincon-Torroella, J., Jackson, C., Bettegowda, C., Weingart, J., & Mukherjee, D. (2024). Hospital frailty risk score predicts high-value care outcomes following brain metastasis resection. Clinical Neurology and Neurosurgery, 245, 108497. https://doi.org/10.1016/j.clineuro.2024.108497

Zhang, C., Zhao, N., Khan, R., Hung, M., Zhang, C., Wang, S., Wang, T. J. C., & Lin, C. (2024). The prognostic significance of androgen receptor expression in gliomas. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-72284-4

Link, K. E., Schnurman, Z., Liu, C., Kwon, Y. J., Jiang, L. Y., Nasir-Moin, M., Neifert, S., Alzate, J. D., Bernstein, K., Qu, T., Chen, V., Yang, E., Golfinos, J. G., Orringer, D., Kondziolka, D., & Oermann, E. K. (2024). Longitudinal deep neural networks for assessing metastatic brain cancer on a large open benchmark. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-52414-2

Latzer, P., Zelba, H., Battke, F., Reinhardt, A., Shao, B., Bartsch, O., Rabsteyn, A., Harter, J., Schulze, M., Okech, T., Golf, A., Kyzirakos-Feger, C., Kayser, S., Pieper, N., Feldhahn, M., Wünsche, J., Seitz, C., Hadaschik, D., Garbe, C., … Biskup, S. (2024). A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51315-8

Chesney, K. M., Keating, G. F., Patel, N., Kilburn, L., Fonseca, A., Wu, C.-C., Nazarian, J., Packer, R. J., Donoho, D. A., Oluigbo, C., Myseros, J. S., Keating, R. F., & Syed, H. R. (2024). The role of focused ultrasound for pediatric brain tumors: current insights and future implications on treatment strategies. Child’s Nervous System, 40(8), 2333–2344. https://doi.org/10.1007/s00381-024-06413-9

Hua, X., Zhou, H., Wu, H.-C., Furnari, J., Kotidis, C. P., Rabadan, R., Genkinger, J. M., Bruce, J. N., Canoll, P., Santella, R. M., & Zhang, Z. (2024). Tumor detection by analysis of both symmetric- and hemi-methylation of plasma cell-free DNA. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-50471-1

Liu, J., Cao, S., Imbach, K. J., Gritsenko, M. A., Lih, T.-S. M., Kyle, J. E., Yaron-Barir, T. M., Binder, Z. A., Li, Y., Strunilin, I., Wang, Y.-T., Tsai, C.-F., Ma, W., Chen, L., Clark, N. M., Shinkle, A., Naser Al Deen, N., Caravan, W., Houston, A., … Ding, L. (2024). Multi-scale signaling and tumor evolution in high-grade gliomas. Cancer Cell, 42(7), 1217-1238.e19. https://doi.org/10.1016/j.ccell.2024.06.004

Arrillaga-Romany, I., Lassman, A., McGovern, S. L., Mueller, S., Nabors, B., van den Bent, M., Vogelbaum, M. A., Allen, J. E., Melemed, A. S., Tarapore, R. S., Wen, P. Y., & Cloughesy, T. (2024). ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-Oncology, 26(Supplement_2), S173–S181. https://doi.org/10.1093/neuonc/noae031

Liu, Z., Mela, A., Argenziano, M. G., Banu, M. A., Furnari, J., Kotidis, C., Sperring, C. P., Humala, N., Mahajan, A., Bruce, J. N., Canoll, P., & Sims, P. A. (2024). Single-cell analysis of 5-aminolevulinic acid intraoperative labeling specificity for glioblastoma. Journal of Neurosurgery, 140(4), 968–978. https://doi.org/10.3171/2023.7.jns23122

IGNATOVA, T. N., CHAITIN, H. J., KUKEKOV, N. V., SUSLOV, O. N., DULATOVA, G. I., HANAFY, K. A., & VRIONIS, F. D. (2024). Gliomagenesis is orchestrated by the Oct3/4 regulatory network. Journal of Neurosurgical Sciences, 68(2). https://doi.org/10.23736/s0390-5616.21.05437-0

Xiao, H., Vaidya, R., Hershman, D. L., & Unger, J. M. (2024). Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022. Journal of Clinical Oncology, 42(16), 1953–1960. https://doi.org/10.1200/jco.23.01777

Lee, I. Y., Hanft, S., Schulder, M., Judy, K. D., Wong, E. T., Elder, J. B., Evans, L. T., Zuccarello, M., Wu, J., Aulakh, S., Agarwal, V., Ramakrishna, R., Gill, B. J., Quiñones-Hinojosa, A., Brennan, C., Zacharia, B. E., Silva Correia, C. E., Diwanji, M., Pennock, G. K., … Boockvar, J. A. (2024). Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients. Future Oncology, 20(10), 579–591. https://doi.org/10.2217/fon-2023-0702

Cao, Q., Hajosch, A., Kast, R. E., Loehmann, C., Hlavac, M., Fischer-Posovszky, P., Strobel, H., Westhoff, M.-A., Siegelin, M. D., Wirtz, C. R., Halatsch, M.-E., & Karpel-Massler, G. (2024). Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British Journal of Cancer, 130(8), 1365–1376. https://doi.org/10.1038/s41416-024-02608-8

Arrillaga-Romany, I., Gardner, S. L., Odia, Y., Aguilera, D., Allen, J. E., Batchelor, T., Butowski, N., Chen, C., Cloughesy, T., Cluster, A., de Groot, J., Dixit, K. S., Graber, J. J., Haggiagi, A. M., Harrison, R. A., Kheradpour, A., Kilburn, L. B., Kurz, S. C., Lu, G., … Wen, P. Y. (2024). ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal of Clinical Oncology, 42(13), 1542–1552. https://doi.org/10.1200/jco.23.01134

Duffau, H., Berger, M., Brastianos, P. K., Sanai, N., Mandonnet, E., & McKhann, G. M. (2024). Introduction: Contemporary management of low-grade gliomas: from tumor biology to the patient’s quality of life. Neurosurgical Focus, 56(2), E1. https://doi.org/10.3171/2023.11.focus23731

Wang, L., Higgins, D., Delgardo, M., Chang, C., Hamberger, M. J., & McKhann, G. M. (2024). Awake intraoperative mapping for the prevention of amusia. Neurosurgical Focus, 56(2), E8. https://doi.org/10.3171/2023.11.focus23600

Giacomini, G., Piquet, S., Chevallier, O., Dabin, J., Bai, S.-K., Kim, B., Siddaway, R., Raught, B., Coyaud, E., Shan, C.-M., Reid, R. J. D., Toda, T., Rothstein, R., Barra, V., Wilhelm, T., Hamadat, S., Bertin, C., Crane, A., Dubois, F., … Polo, S. E. (2024). Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors. Nucleic Acids Research, 52(5), 2372–2388. https://doi.org/10.1093/nar/gkad1257

Avila, E. K., Tobochnik, S., Inati, S. K., Koekkoek, J. A. F., McKhann, G. M., Riviello, J. J., Rudà, R., Schiff, D., Tatum, W. O., Templer, J. W., Weller, M., & Wen, P. Y. (2023). Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management. Neuro-Oncology, 26(1), 7–24. https://doi.org/10.1093/neuonc/noad154

Rahman, R., Trippa, L., Lee, E. Q., Arrillaga-Romany, I., Fell, G., Touat, M., McCluskey, C., Wiley, J., Gaffey, S., Drappatz, J., Welch, M. R., Galanis, E., Ahluwalia, M. S., Colman, H., Nabors, L. B., Hepel, J., Elinzano, H., Schiff, D., Chukwueke, U. N., … Wen, P. Y. (2023). Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Journal of Clinical Oncology, 41(36), 5524–5535. https://doi.org/10.1200/jco.23.00493

Kinslow, C. J., Siegelin, M. D., Iwamoto, F. M., Gallitto, M., Neugut, A. I., Yu, J. B., Cheng, S. K., & Wang, T. J. C. (2023). MGMT promoter methylation in 1p19q-intact gliomas. Journal of Neuro-Oncology, 166(1), 73–78. https://doi.org/10.1007/s11060-023-04515-z

Kinslow, C. J., Cheng, S. K., & Wang, T. J. C. (2023). MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas—Reply. JAMA Oncology, 9(12), 1735. https://doi.org/10.1001/jamaoncol.2023.4754

Al-Dalahmah, O., Argenziano, M. G., Kannan, A., Mahajan, A., Furnari, J., Paryani, F., Boyett, D., Save, A., Humala, N., Khan, F., Li, J., Lu, H., Sun, Y., Tuddenham, J. F., Goldberg, A. R., Dovas, A., Banu, M. A., Sudhakar, T., Bush, E., … Canoll, P. (2023). Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-38186-1

Koschmann, C., Al-Holou, W. N., Alonso, M. M., Anastas, J., Bandopadhayay, P., Barron, T., Becher, O., Cartaxo, R., Castro, M. G., Chung, C., Clausen, M., Dang, D., Doherty, R., Duchatel, R., Dun, M., Filbin, M., Franson, A., Galban, S., Garcia Moure, M., … Venneti, S. (2024). A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell, 42(1), 1–5. https://doi.org/10.1016/j.ccell.2023.11.002

Kinslow, C. J., Rae, A. I., Taparra, K., Kumar, P., Siegelin, M. D., Grinband, J., Gill, B. J. A., McKhann, G. M., Sisti, M. B., Bruce, J. N., Canoll, P. D., Iwamoto, F. M., Horowitz, D. P., Kachnic, L. A., Neugut, A. I., Yu, J. B., Cheng, S. K., & Wang, T. J. C. (2023). MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research, 29(21), 4399–4407. https://doi.org/10.1158/1078-0432.ccr-23-1295

Gondi, V., Deshmukh, S., Brown, P. D., Wefel, J. S., Armstrong, T. S., Tome, W. A., Gilbert, M. R., Konski, A., Robinson, C. G., Bovi, J. A., Benzinger, T. L. S., Roberge, D., Kundapur, V., Kaufman, I., Shah, S., Usuki, K. Y., Baschnagel, A. M., Mehta, M. P., & Kachnic, L. A. (2023). Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. International Journal of Radiation Oncology*Biology*Physics, 117(3), 571–580. https://doi.org/10.1016/j.ijrobp.2023.04.030

Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Larson, J. D., Wechsler-Reya, R. J., Sirianni, R. W., & Elmquist, W. F. (2023). Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors. Journal of Pharmacology and Experimental Therapeutics, 387(3), 315–327. https://doi.org/10.1124/jpet.123.001826

Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., & Morris, V. K. (2024). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology, 20(11), 653–663. https://doi.org/10.2217/fon-2022-1249

Poojar, P., Qian, E., Jin, Z., Fung, M., Maddocks, A. B., & Geethanath, S. (2023). Tailored magnetic resonance fingerprinting of post-operative pediatric brain tumor patients. Clinical Imaging, 102, 53–59. https://doi.org/10.1016/j.clinimag.2023.07.004

Wen, P. Y., van den Bent, M., Youssef, G., Cloughesy, T. F., Ellingson, B. M., Weller, M., Galanis, E., Barboriak, D. P., de Groot, J., Gilbert, M. R., Huang, R., Lassman, A. B., Mehta, M., Molinaro, A. M., Preusser, M., Rahman, R., Shankar, L. K., Stupp, R., Villanueva-Meyer, J. E., … Chang, S. M. (2023). RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. Journal of Clinical Oncology, 41(33), 5187–5199. https://doi.org/10.1200/jco.23.01059

Johnson, M., Bell, A., Lauing, K. L., Ladomersky, E., Zhai, L., Penco-Campillo, M., Shah, Y., Mauer, E., Xiu, J., Nicolaides, T., Drumm, M., McCortney, K., Elemento, O., Kim, M., Bommi, P., Low, J. T., Memon, R., Wu, J., Zhao, J., … Wainwright, D. A. (2023). Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clinical Cancer Research, 29(23), 4973–4989. https://doi.org/10.1158/1078-0432.ccr-23-0834

Raghavendra, U., Gudigar, A., Paul, A., Goutham, T. S., Inamdar, M. A., Hegde, A., Devi, A., Ooi, C. P., Deo, R. C., Barua, P. D., Molinari, F., Ciaccio, E. J., & Acharya, U. R. (2023). Brain tumor detection and screening using artificial intelligence techniques: Current trends and future perspectives. Computers in Biology and Medicine, 163, 107063. https://doi.org/10.1016/j.compbiomed.2023.107063

Rusthoven, C. G., Staley, A. W., Gao, D., Yomo, S., Bernhardt, D., Wandrey, N., El Shafie, R., Kraemer, A., Padilla, O., Chiang, V., Faramand, A. M., Palmer, J. D., Zacharia, B. E., Wegner, R. E., Hattangadi-Gluth, J. A., Levy, A., Bernstein, K., Mathieu, D., Cagney, D. N., … Yamamoto, M. (2023). Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE). JNCI: Journal of the National Cancer Institute, 115(8), 926–936. https://doi.org/10.1093/jnci/djad073

Zheng, C., Wei, Y., Zhang, Q., Sun, M., Wang, Y., Hou, J., Zhang, P., Lv, X., Su, D., Jiang, Y., Gumin, J., Sahni, N., Hu, B., Wang, W., Chen, X., McGrail, D. J., Zhang, C., Huang, S., Xu, H., … Chen, Y. (2023). Multiomics analyses reveal DARS1-AS1 /YBX1–controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance. Science Advances, 9(31). https://doi.org/10.1126/sciadv.adf3984

Berkley, A., Saueressig, C., Shukla, U., Chowdhury, I., Munoz‐Gauna, A., Shehu, O., Singh, R., & Munbodh, R. (2023). Clinical capability of modern brain tumor segmentation models. Medical Physics, 50(8), 4943–4959. Portico. https://doi.org/10.1002/mp.16321

Wu, P. B., Filley, A. C., Miller, M. L., & Bruce, J. N. (2023). Benign Glioma. Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2, 31–71. https://doi.org/10.1007/978-3-031-23705-8_2

Wang, L. M., Englander, Z. K., Miller, M. L., & Bruce, J. N. (2023). Malignant Glioma. Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2, 1–30. https://doi.org/10.1007/978-3-031-23705-8_1

Upadhyayula, P. S., Neira, J. A., Miller, M. L., & Bruce, J. N. (2023). Benign and Malignant Tumors of the Pineal Region. Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2, 153–173. https://doi.org/10.1007/978-3-031-23705-8_6

Kinslow, C. J., Mercurio, A., Kumar, P., Rae, A. I., Siegelin, M. D., Grinband, J., Taparra, K., Upadhyayula, P. S., McKhann, G. M., Sisti, M. B., Bruce, J. N., Canoll, P. D., Iwamoto, F. M., Kachnic, L. A., Yu, J. B., Cheng, S. K., & Wang, T. J. C. (2023). Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy. JAMA Oncology, 9(7), 919. https://doi.org/10.1001/jamaoncol.2023.0990

Ellingson, B. M., Wen, P. Y., Chang, S. M., van den Bent, M., Vogelbaum, M. A., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A. B., Gilbert, M. R., de Groot, J. F., Weller, M., Galanis, E., & Cloughesy, T. F. (2023). Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology, 25(6), 1017–1028. https://doi.org/10.1093/neuonc/noad002

Mair, M. J., Bartsch, R., Le Rhun, E., Berghoff, A. S., Brastianos, P. K., Cortes, J., Gan, H. K., Lin, N. U., Lassman, A. B., Wen, P. Y., Weller, M., van den Bent, M., & Preusser, M. (2023). Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nature Reviews Clinical Oncology, 20(6), 372–389. https://doi.org/10.1038/s41571-023-00756-z

Ramkissoon, S. H., Fernandes, H., Lopez-Terrada, D. H., Hameed, M. R., Trembath, D. G., Bridge, J. A., Lindeman, N. I., Souers, R. J., Vasalos, P., Brat, D. J., & Moncur, J. T. (2022). Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors. Archives of Pathology & Laboratory Medicine, 147(5), 518–524. https://doi.org/10.5858/arpa.2021-0431-cp

Cocito, C., Martin, B., Giantini-Larsen, A. M., Valcarce-Aspegren, M., Souweidane, M. M., Szalontay, L., Dahmane, N., & Greenfield, J. P. (2023). Leptomeningeal dissemination in pediatric brain tumors. Neoplasia, 39, 100898. https://doi.org/10.1016/j.neo.2023.100898

Alkazemi, M., Lo, Y. T., Hussein, H., Mammi, M., Saleh, S., Araujo-Lama, L., Mommsen, S., Pisano, A., Lamba, N., Bunevicius, A., & Mekary, R. A. (2023). Laser Interstitial Thermal Therapy for the Treatment of Primary and Metastatic Brain Tumors: A Systematic Review and Meta-Analysis. World Neurosurgery, 171, e654–e671. https://doi.org/10.1016/j.wneu.2022.12.079

Gao, S., Jin, L., Moliterno, J., Corbin, Z. A., Bindra, R. S., Contessa, J. N., Yu, J. B., & Park, H. S. (2023). Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. Journal of Neurosurgery, 138(3), 610–620. https://doi.org/10.3171/2022.5.jns212761

Lassman, A. B., Pugh, S. L., Wang, T. J. C., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., Moazami, G., Macsai, M. S., Gilbert, M. R., Bain, E. E., Blot, V., Ansell, P. J., Samanta, S., Kundu, M. G., Armstrong, T. S., … Mehta, M. P. (2022). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 25(2), 339–350. https://doi.org/10.1093/neuonc/noac173

Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., Salacz, M. E., D’Andre, S., Aiken, R. D., Moshel, Y. A., Nam, J. Y., Pillainayagam, C. P., Wagner, S. A., Walter, K. A., Chaudhary, R., … Bosch, M. L. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. JAMA Oncology, 9(1), 112. https://doi.org/10.1001/jamaoncol.2022.5370